{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:36:36Z","timestamp":1770824196492,"version":"3.50.1"},"reference-count":130,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":181,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:p>KIT is a member of the tyrosine kinase family of growth factor receptors which is expressed on a variety of haematopoietic cells including mast cells. Stem cell factor (SCF)\u2010dependent activation of KIT is critical for mast cell homeostasis and function. However, when KIT is inappropriately activated, accumulation of mast cells in tissues results in mastocytosis. Such dysregulated KIT activation is a manifestation of specific activating point mutations within KIT, with the human D816V mutation considered as a hallmark of human systemic mastocytosis. A number of other activating mutations in KIT have recently been identified and these mutations may also contribute to aberrant mast cell growth. In addition to its role in mast cell growth, differentiation and survival, localized concentration gradients of SCF may control the targeting of mast cells to specific tissues and, once resident within these tissues, mast cell activation by antigen may also be amplified by SCF. Thus, KIT inhibitors may have potential application in multiple conditions linked to mast cells including systemic mastocytosis, anaphylaxis, and asthma. In this review, we discuss the role of KIT in the context of mast cells in these disease states and how recent advances in the development of inhibitors of KIT activity and function may offer novel therapies for the treatment of these disorders.<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2008) <jats:bold>154<\/jats:bold>, 1572\u20131582; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/bjp.2008.204\">10.1038\/bjp.2008.204<\/jats:ext-link>; published online 26 May 2008<\/jats:p>","DOI":"10.1038\/bjp.2008.204","type":"journal-article","created":{"date-parts":[[2008,5,26]],"date-time":"2008-05-26T10:16:25Z","timestamp":1211796985000},"page":"1572-1582","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders"],"prefix":"10.1111","volume":"154","author":[{"given":"B M","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Gilfillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2006-07-032714","article-title":"Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412","volume":"109","author":"Aichberger KJ","year":"2007","journal-title":"Blood"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2006.060022"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(03)00112-7"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3816"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.046"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-028100"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.01975.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700125"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116749"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313381200"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.726"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.4.1345"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.8.2145.2145"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701385181"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.3602"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2189"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2681"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.1.213"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1998.275.5.C1291"},{"key":"e_1_2_11_21_1","first-page":"3127","article-title":"The pyrido[2,3\u2010d]pyrimidine derivative PD180970 inhibits p210Bcr\u2010Abl tyrosine kinase and induces apoptosis of K562 leukemic cells","volume":"60","author":"Dorsey JF","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21996"},{"key":"e_1_2_11_23_1","first-page":"17","article-title":"PKC412\u2014a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro D","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90299-T"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000083954"},{"key":"e_1_2_11_26_1","first-page":"107","article-title":"Histamine in idiopathic inflammatory bowel diseases\u2014not a standby player","volume":"46","author":"Fogel WA","year":"2005","journal-title":"Folia Med Cracov"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2477"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116761"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2433"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1158"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015545"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1782"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-3022"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11339"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1568"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"1035a","DOI":"10.1182\/blood.V110.11.3536.3536","article-title":"The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a Phase II trial","volume":"110","author":"Gotlib J","year":"2007","journal-title":"Blood"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.06.008"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.925"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00017a026"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"764a","DOI":"10.1182\/blood.V108.11.2703.2703","article-title":"A phase II study of nilotinib, a novel inhibitor of c\u2010kit, PDGFR, and Bcr\u2010Abl, administered to patients with systemic mastocytosis","volume":"108","author":"Hochhaus A","year":"2006","journal-title":"Blood"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2004.01.005"},{"key":"e_1_2_11_44_1","first-page":"2345","article-title":"Specific c\u2010kit mutations in sinonasal natural killer\/T\u2010cell lymphoma in China and Japan","volume":"60","author":"Hongyo T","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90303-V"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506063200"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.125237"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152807780077255"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029835"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.879"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.4586"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V53.3.492.492"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V52.2.447.447"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2006.05.004"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1159\/000236929"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.3.790.bloodjournal853790"},{"key":"e_1_2_11_58_1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.V88.3.995.995","article-title":"Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c\u2010kit receptor tyrosine kinase","volume":"88","author":"Kitayama H","year":"1996","journal-title":"Blood"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0006"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2798"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4163223.x"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210159"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.4.2089"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2007.08.007"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11836"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2004.08.015"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2004-0117"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.2.678"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.75.103004.142657"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.03.012"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(99)00078-3"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.43.27450"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1377"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.21458"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.966"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1741"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290803"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310820"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780300202"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.05.024"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1997.77.4.1033"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.1995.tb00250.x"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403319200"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300186200"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00577.x"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10560"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.8.3717"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1385\/IR:34:2:97"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.00019.x"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-013805"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14115-3"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1627"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00065-1"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800907781386614"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2275"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.9.5915"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2322"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.12.067"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.04.015"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.08.055"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.09.150"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2005.11.005"},{"key":"e_1_2_11_103_1","first-page":"117","article-title":"A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases","volume":"5","author":"Scheinfeld N","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600445103"},{"key":"e_1_2_11_105_1","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1016\/S0021-9258(17)37564-6","article-title":"Tyrosine residue 719 of the c\u2010kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3\u2010kinase and for c\u2010kit\u2010associated PI 3\u2010kinase activity in COS\u20101 cells","volume":"269","author":"Serve H","year":"1994","journal-title":"J Biol Chem"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-3969"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2004.06.004"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-007-0007-2"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1601"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3247"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.1195"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-1578(10)60529-6"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.02.013"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-72005-0_45"},{"issue":"1","key":"e_1_2_11_115_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bj3410211","article-title":"Identification of Tyr\u2010703 and Tyr\u2010936 as the primary association sites for Grb2 and Grb7 in the c\u2010Kit\/stem cell factor receptor","volume":"341","author":"Thommes K","year":"1999","journal-title":"Biochem J"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65419-3"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2769"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2006.05.011"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.16.7350"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-003-2349-8"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00168-6"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04575.x"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3406.h8003406_3406_3413"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050231m"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.04.005"},{"key":"e_1_2_11_127_1","doi-asserted-by":"crossref","first-page":"1036a","DOI":"10.1182\/blood.V108.11.3627.3627","article-title":"Dasatinib (Sprycel (TM)) therapy for patients with systemic mastocytosis","volume":"108","author":"Verstovsek S","year":"2006","journal-title":"Blood"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1987.tb02655.x"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.2.313"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050807"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206120"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fbjp.2008.204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fbjp.2008.204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/bjp.2008.204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T15:39:57Z","timestamp":1697125197000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/bjp.2008.204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":130,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1038\/bjp.2008.204"],"URL":"https:\/\/doi.org\/10.1038\/bjp.2008.204","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}